Bio-based ingredient and polymer manufacturing is forging ahead. 

Mojia Biotech, a Shanghai-based biomanufacturing company has completed an $80 million Series B. The funds will be used to commercialize its bio-based animal feed additives, scale up biomanufacturing capacity, advance its product pipeline, and expand its global R&D capabilities.  

Temasek led the round, with participation from LYZZ Capital and Sento Investment. Bits x Bites continued to back the company, along with Asia Green Fund. 

For over a century, petroleum-based chemical manufacturing has contributed to greenhouse gas emissions and climate change. It’s about time we move to greener and safer production by switching toward renewable feedstock and by incorporating advances in synthetic biology in manufacturing.

With its proprietary platform for enzyme and metabolic engineering, Mojia is transforming the chemical and polymer space, starting with vitamin B5. Compared to traditional approaches, Mojia’s patented bioprocess consumes less energy and emits less waste. It also ensures stable supply of vitamin B5 free from frequent production disruptions caused by tightening environmental regulations in China.  

Its second product is a series of biopolymer products for coating and adhesive applications.  

Joseph Zhou, managing partner of Bits x Bites, says: “Sustainable ingredient manufacturing is a pillar for a thriving green economy. And with the recent delays and shortages in the global supply chain highlighting the importance to reduce reliance on raw material imports, we see huge potential for Mojia Biotech to apply its technology across different chemical ingredients, and to become a leader for next-generation green chemical production. ”